{"organizations": [], "uuid": "29a376c7ea7e44b1fd0d05f7dce77e9c681dd953", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000551/device/rss", "section_title": "California", "url": "https://www.cnbc.com/2018/05/10/the-associated-press-halozyme-therapeutics-1q-earnings-snapshot.html", "country": "US", "domain_rank": 767, "title": "Halozyme Therapeutics: 1Q Earnings Snapshot", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-11T00:44:00.000+03:00", "replies_count": 0, "uuid": "29a376c7ea7e44b1fd0d05f7dce77e9c681dd953"}, "author": "cnbc.com", "url": "https://www.cnbc.com/2018/05/10/the-associated-press-halozyme-therapeutics-1q-earnings-snapshot.html", "ord_in_thread": 0, "title": "Halozyme Therapeutics: 1Q Earnings Snapshot", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}], "organizations": [{"name": "halozyme therapeutics inc.", "sentiment": "negative"}, {"name": "ap", "sentiment": "negative"}, {"name": "zacks investment research", "sentiment": "none"}, {"name": "halozyme therapeutics", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "SAN DIEGO (AP) _ Halozyme Therapeutics Inc. (HALO) on Thursday reported a loss of $27.5 million in its first quarter.\nOn a per-share basis, the San Diego-based company said it had a loss of 19 cents.\nThe results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research was for a loss of 21 cents per share.\nThe biopharmaceutical company posted revenue of $30.9 million in the period, also exceeding Street forecasts. Three analysts surveyed by Zacks expected $29.5 million.\nHalozyme Therapeutics expects full-year revenue in the range of $115 million to $125 million.\nHalozyme Therapeutics shares have declined slightly more than 1 percent since the beginning of the year. In the final minutes of trading on Thursday, shares hit $19.97, a rise of 47 percent in the last 12 months.\nThis story was generated by Automated Insights ( http://automatedinsights.com/ap ) using data from Zacks Investment Research. Access a Zacks stock report on HALO at https://www.zacks.com/ap/HALO", "external_links": ["https://www.zacks.com/ap/HALO", "http://automatedinsights.com/ap"], "published": "2018-05-11T00:44:00.000+03:00", "crawled": "2018-05-11T00:14:59.006+03:00", "highlightTitle": ""}